Opus Genetics, Inc. $IRD

What the company doesAI summary of filing

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to treat inherited retinal diseases and other ophthalmic disorders. The company's pipeline includes seven adeno-associated virus-based gene therapy programs for conditions such as LCA5, BEST1, RHO, and others, along with phentolamine ophthalmic solution for multiple indications including pharmacologically induced mydriasis (FDA-approved and commercially available as RYZUMVI), presbyopia, and low-light vision disturbances. The company generates revenue through a license agreement with Viatris for phentolamine development and commercialization, having received an upfront payment of $35 million and milestone payments, with additional royalties expected upon future approvals. Opus' gene therapy programs are in clinical or preclinical development stages, with the most advanced program, OPGx-LCA5, in Phase 1/2 trials. [10-K 2026-03-12]

Segments: Gene therapies (seven AAV-based programs: OPGx-LCA5, OPGx-BEST1, OPGx-RHO, OPGx-RDH12, OPGx-NMNAT1, OPGx-MERTK, OPGx-CNGB1), Phentolamine Ophthalmic Solution 0.75% (RYZUMVI), APX3330 (Ref-1 inhibitor for diabetic retinopathy)